What Globus Medical’s Recent Share Moves Signal for Investors

Globus Medical (GMED) shares recently closed at $90.18, with mixed short term returns, including a 2.7% gain over the past day and a 4.5% rise over the past month.

Zooming out, the recent 1 day share price return of 2.7% sits against a more modest 30 day share price return of 4.7% and a stronger 1 year total shareholder return of 26.8%. Taken together, these figures suggest momentum has been building over a longer horizon even as shorter term moves remain choppy.

If you are weighing Globus Medical against other healthcare names, this is a good moment to scan the wider space and see what stands out in 33 healthcare AI stocks

With Globus Medical trading at $90.18, alongside an indicated 32% intrinsic discount and a 23% gap to the average analyst target, you need to ask yourself: is there a genuine opportunity here, or is future growth already priced in?

Most Popular Narrative: 18.1% Undervalued

The most followed narrative pegs Globus Medical’s fair value at $110.08 versus the last close at $90.18, framing the current price as a meaningful discount before you look at the finer print.

Continued innovation and adoption of robotics, navigation, and minimally invasive procedures, including expansion of the ExcelsiusGPS ecosystem, launch of the Excelsius XR headset, and robust product pipeline, position Globus to capitalize on healthcare digitization trends, driving higher ASPs, stronger market differentiation, and improved gross margins over time.

Want to see what kind of revenue path and margin profile sits behind that fair value tag, and how rich a future earnings multiple this narrative builds in?

Result: Fair Value of $110.08 (UNDERVALUED)

However, this story can change quickly if Nevro integration stumbles or if international sales stay sluggish, putting the current margin and growth assumptions under pressure.

Another Angle on Valuation

The story looks different once you focus on the share price against earnings. Globus Medical trades on a P/E of 22.7x, which sits close to its fair ratio of 22.2x and slightly below the US Medical Equipment industry at 23.3x, while also standing well under peers at 42.2x. That mix of near fair ratio, cheaper industry comparison, and much lower peer multiple raises a simple question for you: is this a margin of safety or a sign expectations are already full?

Next Steps

With sentiment leaning cautiously positive so far, this is a good time to look through the numbers yourself and decide whether the optimism feels justified. To see what others view as the main strengths before you make up your mind, review the 4 key rewards

Looking for more investment ideas?

If Globus Medical is on your radar, this is a good time to widen your watchlist and line up a few more candidates that might fit your style.

• Spot potential value setups early by scanning 51 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect them yet.
• Prioritise resilience with 74 resilient stocks with low risk scores so you can focus on companies that score well on financial strength and volatility checks.
• Get ahead of the crowd by reviewing the screener containing 25 high quality undiscovered gems before other investors start paying closer attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.